secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001610618-24-000043
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cidara reports FY2023 net loss $22.9M; effects 1-for-20 reverse stock split
---------------------------------------------------------------------------

- Net loss $22.9M in FY2023 ($33.6M in 2022); revenue $63.9M. Cash $35.8M at Dec 31, 2023.
- 1-for-20 reverse stock split effective April 23, 2024; shares begin trading split-adjusted April 24.
- REZZAYO approved in EU and UK; Cidara received $11.1M and $2.8M milestone payments.
- IND for lead oncology DFC CBO421 expected mid-2024; Phase 3 ReSTORE China data expected Q2 2024.
- Financial results restated to correct understated accrued liabilities and operating expenses from indirect taxes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/cdtx-20240422.htm
  HTML page:      https://secwatch.observer/filing/0001610618-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer